Immuron announces travelan® clinical study cohort 2 commences

Highlights: second cohort of 34 healthy volunteers enrolled in the travelan® clinical trial clinical trial to examine a dosing regimen for travelan® more suited to the us military has commenced the second cohort the clinical study 6 month follow up of cohorts 1 and 2 anticipated to be completed in april 2024 travelan® is known to protect against the onset of traveler's diarrhea (td), the most common illness reported by travelers melbourne, australia, oct. 18, 2023 (globe newswire) -- immuron limited (asx: imc; nasdaq: imrn), an australian based and globally integrated biopharmaceutical company, is pleased to announce the second cohort of 34 participants have commenced the clinical trial to evaluate the efficacy of travelan® to prevent infectious diarrhea caused by enterotoxigenic escherichia coli (etec). the clinical study is being led by principal investigator dr mohamed al-ibrahim at the pharmaron cpc fda inspected clinical research facility inpatient unit located in baltimore, maryland us.
IMRN Ratings Summary
IMRN Quant Ranking